This article has been cited by
1Sex steroids in the tumor microenvironment and prostate cancer progression
Clovis Boibessot,Paul Toren
Endocrine-Related Cancer.2018;25(3)R179
2Discordance between testosterone measurement methods in castrated prostate cancer patients
Mélanie Rouleau,Francis Lemire,Michel Déry,Benoît Thériault,Gabriel Dubois,Yves Fradet,Paul Toren,Chantal Guillemette,Louis Lacombe,Laurence Klotz,Fred Saad,Dominique Guérette,Frédéric Pouliot
Endocrine Connections.2019;8(2)132
3Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
Shengri Tian,Zhen Lei,Zuo Gong,Zhonghai Sun,Dongyuan Xu,Minhu Piao
Cancer Cell International.2020;20(1)132
4Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel
Keisuke Ando,Shinichi Sakamoto,Nobushige Takeshita,Ayumi Fujimoto,Maihulan Maimaiti,Shinpei Saito,Pae Sanjyon,Yusuke Imamura,Nobuo Sato,Akira Komiya,Koichiro Akakura,Tomohiko Ichikawa
The Prostate.2020;80(3)247
5Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
Yinghao Sun,Liping Xie,Tao Xu,Jørn S. Jakobsen,Weiqing Han,Per S. Sørensen,Xiaofeng Wang
Asian Journal of Urology.2020;7(3)301
6Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis
Mélanie Claps,Fausto Petrelli,Orazio Caffo,Vito Amoroso,Elisa Roca,Alessandra Mosca,Francesca Maines,Sandro Barni,Alfredo Berruti
Clinical Genitourinary Cancer.2018;16(3)165

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal